Overview

This trial is active, not recruiting.

Condition cardiovascular disease
Sponsor Ottawa Heart Institute Research Corporation
Start date June 2013
End date June 2017
Trial size 4000 participants
Trial identifier NCT02019212, 20130446-01H

Summary

The purpose of this study is to evaluate the quality and prognostic ability of low dose 99mTc-tetrofosmin Myocardial Perfusion SPECT Imaging.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Arm
Clinical patients who have undergone myocardial perfusion imaging with 99mTc

Primary Outcomes

Measure
Cardiovascular Outcomes
time frame: 15 minutes

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Participants who have completed the FD and LD MPI studies on the GE Infinia Haweye or GE NM 530 (CZT crystal) cameras - Retrospective participants must consent to the study interview(s) for data collection - Prospective participants must consent to follow up for data collection Exclusion Criteria: - Unwilling to consent to data collection either retrospectively or in follow up prospectively

Additional Information

Official title Prognostic Value of Stress SPECT Myocardial Perfusion Imaging With Half Dose 99mTc-tetrofosmin
Principal investigator Renée Hessian, MD
Description The objective of this study is to determine if myocardial perfusion imaging (MPI) using a new SPECT reconstruction software and a low dose (LD) of 99mTC-tetrofosmin will provide equal quality and prognostic value as a full dose (FD) of 99mTc-tetrofosmin myocardial perfusion SPECT imaging methodology. The images of clinical patients from the Diagnostic Imaging Department will be assessed and compared for image quality and myocardial perfusion. The outcomes of participants that have had FD studies will be compared to those who have had LD studies. Consented participants will be contacted and will be asked to provide information on their cardiovascular health since the date of their LD or FD scan, such as non fatal myocardial infarction, death, congestive heart failure, admission to hospital with chest pain, further cardiac diagnostic testing, including angiography and early and late revascularization. The event information will be tabulated at 6, 12, 18, and 24 months for the LD and FD studies. The study hypothesizes that there will be no difference in the quality and prognostic value between the LD and FD 99mTc-tetrofosmin SPECT MPI imaging protocols. The study hypothesizes that there will be no increase in repeat diagnostic testing and angiography with using the LD imaging protocol.
Trial information was received from ClinicalTrials.gov and was last updated in February 2016.
Information provided to ClinicalTrials.gov by Ottawa Heart Institute Research Corporation.